Orchestra Biomed Hldgs Inc (OBIO) Stock Price, Quote & News

Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications;...

Industry: Biotechnology

Sector: Healthcare

Phone: 215 862 5797

Website: orchestrabiomed.com

Address:

150 Union Square Drive, New Hope, United States

Iightning Dec. 5 at 6:34 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 5.36 Return: +55.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:23 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 5.36 Return: +55.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:02 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 4.35 Return: +26.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Mptxop Dec. 3 at 4:11 PM

$OBIO we may see a little more downward movement before it goes back to 6$.

0 · Reply

Iightning Dec. 3 at 10:49 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 4.63 Return: +34.26% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 2:33 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $OBIO **Contract:** Dec 19 $5C **Entry:** 0.41 **Exit:** 0.59 **Return:** **+42.96% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

ppl_first Nov. 26 at 4:00 PM

$OBIO was able to sell today, no loss, no gain. Volume really tells the story, not the news. There isn’t any volume to speak of.

0 · Reply

Iightning Nov. 26 at 5:29 AM

1ightning® Options Trade Alert (Actionable) | Buy $OBIO Dec 19 $5 Call | Enter: $0.31 Exit: $0.57 | Profit: 82.31% ROI | https://1ightning.com

0 · Reply

ppl_first Nov. 26 at 12:50 AM

$OBIO oh shit! Got ‘em. Nice rug pull on us retail bag holders. Selling at another loss.

1 · Reply

ppl_first Nov. 25 at 9:59 PM

$OBIO Can't hold its own after hours, scary for tomorrow morning.

0 · Reply

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 11, 2025, 9:00 AM EST - 23 days ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

MDT

Nov 10, 2025, 4:10 PM EST - 24 days ago

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Nov 3, 2025, 8:00 AM EST - 4 weeks ago

Orchestra BioMed to Host Business Update Call on November 12, 2025

MDT

Oct 28, 2025, 8:00 AM EDT - 5 weeks ago

Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements

Oct 27, 2025, 9:00 AM EDT - 5 weeks ago

Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial

Oct 9, 2025, 8:00 AM EDT - 2 months ago

Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit

MDT

Sep 4, 2025, 5:00 PM EDT - 3 months ago

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Aug 14, 2025, 8:00 AM EDT - 4 months ago

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Aug 12, 2025, 8:14 AM EDT - 4 months ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 8, 2025, 7:00 AM EDT - 4 months ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Aug 5, 2025, 7:00 AM EDT - 4 months ago

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Aug 1, 2025, 7:59 AM EDT - 4 months ago

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Jul 31, 2025, 4:02 PM EDT - 4 months ago

Orchestra BioMed Announces Proposed Public Offering

Jul 31, 2025, 4:01 PM EDT - 4 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

LGND MDT

Jun 18, 2025, 9:30 AM EDT - 6 months ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

May 28, 2025, 7:20 AM EDT - 6 months ago

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 12, 2025, 4:28 PM EDT - 7 months ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 7, 2025, 8:30 AM EDT - 7 months ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Apr 29, 2025, 9:00 AM EDT - 7 months ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 23, 2025, 9:00 AM EDT - 8 months ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Apr 22, 2025, 7:00 AM EDT - 8 months ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Mar 31, 2025, 4:21 PM EDT - 8 months ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Feb 20, 2025, 8:00 AM EST - 10 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 18, 2025, 8:00 AM EST - 10 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 12, 2025, 10:43 AM EST - 10 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 5, 2025, 8:00 AM EST - 10 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Nov 26, 2024, 4:05 PM EST - 1 year ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:12 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

May 22, 2024, 8:43 AM EDT - 1 year ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 13, 2024, 4:58 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Mar 27, 2024, 4:17 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 7, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 6, 2024, 8:37 AM EST - 1 year ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 2 years ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Nov 13, 2023, 4:21 PM EST - 2 years ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 19, 2023, 12:23 PM EDT - 2 years ago

Why Shares of Orchestra BioMed Jumped Tuesday

Sep 19, 2023, 7:30 AM EDT - 2 years ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Aug 10, 2023, 4:34 PM EDT - 2 years ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Jun 28, 2023, 2:16 PM EDT - 2 years ago

Why Shares of Orchestra BioMed Holdings Jumped Wednesday

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 7, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

May 12, 2023, 9:15 AM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Mar 24, 2023, 3:52 PM EDT - 2 years ago

Why Shares of Orchestra BioMed Jumped This Week

Feb 24, 2023, 8:00 AM EST - 3 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Iightning Dec. 5 at 6:34 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 5.36 Return: +55.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 5 at 12:23 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 5.36 Return: +55.43% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:02 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 4.35 Return: +26.12% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Mptxop Dec. 3 at 4:11 PM

$OBIO we may see a little more downward movement before it goes back to 6$.

0 · Reply

Iightning Dec. 3 at 10:49 AM

1ightning® Premium Options Alert (Actionable) Ticker: $OBIO Contract: Dec 19 $2.5C Entry: 3.45 Exit: 4.63 Return: +34.26% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 2 at 2:33 AM

0 · Reply

ppl_first Nov. 26 at 4:00 PM

$OBIO was able to sell today, no loss, no gain. Volume really tells the story, not the news. There isn’t any volume to speak of.

0 · Reply

Iightning Nov. 26 at 5:29 AM

1ightning® Options Trade Alert (Actionable) | Buy $OBIO Dec 19 $5 Call | Enter: $0.31 Exit: $0.57 | Profit: 82.31% ROI | https://1ightning.com

0 · Reply

ppl_first Nov. 26 at 12:50 AM

$OBIO oh shit! Got ‘em. Nice rug pull on us retail bag holders. Selling at another loss.

1 · Reply

ppl_first Nov. 25 at 9:59 PM

$OBIO Can't hold its own after hours, scary for tomorrow morning.

0 · Reply

RunnerSignals Nov. 25 at 9:18 PM

Comeback Kings Alert 🔥 $CIFR $OBIO $ADI $PACB $LAES bounced HARD from session lows! One rallied 10%+ from the bottom https://stocksrunner.com/news/2025-11-25-10-stocks-that-refused-to-stay-down-today

0 · Reply

Pkinla Nov. 25 at 8:12 PM

$OBIO what’s cooking !?

1 · Reply

makedatbread88 Nov. 25 at 7:37 PM

$OBIO just every day keeps going higher ***FOLLOW ME for more winning calls!***

0 · Reply

ppl_first Nov. 25 at 7:19 PM

$OBIO The company announced they secured over $111 million in proceeds and committed capital from strategic investors, which strengthens the balance sheet and runway.

0 · Reply

ppl_first Nov. 25 at 7:17 PM

$OBIO OBIO does not look like a dilution trap. They have real cash, real investment backing, and a multi-year runway. That said, I'm in at 5.28 with a tight stop loss at 5.20.

0 · Reply

ppl_first Nov. 25 at 7:12 PM

$OBIO 32M float $42 million in cash and equivalents $53.8 million in marketable securities $30 million strategic investment announced afterward Total accessible capital: roughly $125–$130 million. This is not a distressed microcap profile. This is legitimate runway.

0 · Reply

DaBullRunner Nov. 25 at 7:02 PM

$OBIO there it goes …. 🚨INM🚨adding as they have multiple catalysts coming up it deals with ALZHEIMER’S This is my next ATHE👇💰💰💰

0 · Reply

Mptxop Nov. 25 at 6:04 PM

$OBIO This is in beast mode!

0 · Reply

Iightning Nov. 25 at 3:38 PM

1ightning® Options Trade Alert (Actionable) | Buy $OBIO Dec 19 $5 Call | Enter: $0.31 Exit: $0.57 | Profit: 82.31% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:32 AM

1ightning® Options Trade Alert (Actionable) | Buy $OBIO Dec 19 $5 Call | Enter: $0.31 Exit: $0.57 | Profit: 82.31% ROI | https://1ightning.com

0 · Reply

makedatbread88 Nov. 25 at 12:33 AM

$OBIO took months to move and finally moved big… such a monster move after it was beaten down heavily originally after bullish private placements You know what else has a bullish private placement and has been destroyed for months now? Ticker $SGD 😉 If you’re not in SGD below the $1.36 private placement price, you probably should consider a position 😊😃 ***FOLLOW ME for more winning calls!***

0 · Reply

BinaryLogic Nov. 25 at 12:25 AM

$OBIO [Correct]

1 · Reply

Market Cap	269.34M
Revenue (ttm)	2.64M
Net Income (ttm)	-61.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,311.36%
Debt to Equity Ratio	0.32

Volume	156,300
Avg Vol	328,208
Day's Range	N/A - N/A
Shares Out	56.47M
Stochastic %K	42%
Beta	0.62
Analysts	Strong Sell
Price Target	$13.33